Navigation Links
Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
Date:7/11/2012

http://www.silence-therapeutics.com).  Copies of the Circular will be also available from the offices of Silence plc, The Royal Institution of Great Britain, 21 Albermarle Street, London, W1S 4BS and at the offices of Covington & Burling LLP, 265 Strand, London, WC2R 1BH.

Jerry Randall, Chairman, said: "In very challenging markets, Silence Therapeutics has secured commitments from existing and new shareholders to raise at least £5.2 million. Over the next two years we expect to conclude multiple value-driving events including completion of a second clinical trial of Atu027. The proceeds from this fundraising will strengthen the balance sheet with a view to ensuring that Silence extracts the highest value from its products and RNAi technology platform."

Background to and Reasons for the Fundraising and Use of Proceeds

On 21 March 2012, the Company announced its unaudited preliminary results for the 12 months ended 31 December 2011. In this announcement, the Company disclosed that the Group had cash resources which, based on the current levels of cash expenditure, are expected to last into the second half of 2012. As a consequence, the Group stated that it would require additional finance at some point in the future to enable its strategy for creating Shareholder value to be implemented in an optimal manner.

It is the intention of the Directors that the amount of £5.2 million (before costs) being raised from the Subscription and the Convertible Loan Note will be used to support the development of the RNAi platform as outlined below.

The proceeds of the Fundraising will enhance the Group's financial position and provide it with sufficient cash resources to fund the business until 2014. This injection of funding would extend the existing window of opportunity for exploitation of the RNAi platform and the Company's lead development candidate Atu027. In particular, it would enable the Company t
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
2. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
3. Silence Therapeutics Additional Listing
4. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
5. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
6. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
7. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
8. Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report
9. United Therapeutics Announces Additional $100 Million Share Repurchase Program
10. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
11. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... & Rockville, MD (PRWEB) July 29, 2014 ... Inc. (ITI), a vaccine pioneer in the biotechnology ... services firm Newport Coast Securities, Inc. to explore ... is commercializing LAMP-vax technology, a breakthrough vaccine platform ... and immunotherapy market. The company exclusively licensed the ...
(Date:7/29/2014)... 29, 2014  Sigma-Aldrich Corporation (NASDAQ: SIAL ... increased its investment in Green Chemistry and donated more ... last year, the Company announced Monday in its new ... the World? The report comes in ... being a responsible corporate citizen, including recognition for the ...
(Date:7/29/2014)...  United Therapeutics Corporation (NASDAQ: ... for the second quarter ended June 30, 2014. ... our medicines are reaching increasing numbers of ... said Martine Rothblatt, Ph.D., United Therapeutics, Chairman ... this quarter of our extended-release tablet called ...
(Date:7/29/2014)... 29, 2014 Eppendorf Centrifuge 5427 ... selection. Eppendorf 5427 R is geared towards high-end applications ... it is targeted towards work requiring high sample throughput. ... as it compliments their extensive 16, 48, and 64 ... microcentrifuge tubes, PCR tubes, PCR strip tubes, and more. ...
Breaking Biology Technology:Immunomic Therapeutics Engages Newport Coast Securities, Inc. 2Immunomic Therapeutics Engages Newport Coast Securities, Inc. 3Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13International Pipette Distributor, Pipette.com Announces the Addition of the Eppendorf Centrifuge 5427 R to Their Product Portfolio 2
... energy company, BioPower Systems (BPS), today announced that the ... O,Brien MP, has awarded the company conditional funding support ... Program. The funding will be applied towards ... bioWAVE ocean wave energy system at a grid-connected site ...
... Medical Center researchers could still be close to giving heart ... The "LateTIME" trial was a study of adult ... to have the ability to improve heart function after an ... the attack. Results were released this week ...
... Palatin Technologies, Inc. (NYSE Amex: ... peptide therapeutics for the treatment of diseases with ... announced that Dr. Carl Spana, President and Chief ... Area Partnerships conference on Thursday, December 1, 2011.  ...
Cached Biology Technology:BioPower Systems Awarded $5 Million from Victorian Government 2BioPower Systems Awarded $5 Million from Victorian Government 3Post Heart Attack Recovery Not Aided By Stem Cell Injections, But Trial Demonstrates Promise 2Palatin Technologies to Present at Windhover's Therapeutic Area Partnerships Conference 2
(Date:7/29/2014)... in locomotion. Swimming microorganisms, such as bacteria and spermatozoa, ... the viscous forces exerted by the surrounding fluid. ... scientists have found that the direction of propulsion made ... by a viscoelastic fluid. These findings have been published ... the Alternative Energies and Atomic Energy Commission (CEA), in ...
(Date:7/29/2014)... wildfires that have been plaguing the Northern Territories in ... Great Lakes in the U.S. continue on. NASA,s ... Resolution Imaging Spectroradiometer, MODIS, instrument on July 26, 2014. ... outlined in red. Copious amount of smoke are drifting ... havoc for residents of Yellowknife. Fire has caused ...
(Date:7/29/2014)... the University of Kent has shown for the first ... a breakthrough that could have a major impact on ... of Biosciences uncovered the mechanism whereby the physical properties ... actin filaments are ,fine-tuned, to undertake different functions. ... completely stable, providing a framework for the cell, others ...
Breaking Biology News(10 mins):Optimum inertial self-propulsion design for snowman-like nanorobot 2
... GOCE satellite from the Plesetsk cosmodrome in northern Russia had ... due to an anomaly identified in one of the units ... stage (Breeze KM ). The correction of the problem ... perform this operation, it will be necessary to de-mate the ...
... physician-geneticist and leader of the Human Genome Project, has ... the Inamori International Center for Ethics and Excellence at ... and Kyoto Prizes for science, technology, philosophy and the ... ethical leaders. It is presented annually to an individual ...
... de los Alimentos (Institute of Nutrition and Food Technology) ... doing research into the positive effects of Mediterranean diet,s ... is a new research line about pancreatic cancer cells. ... points out that in the study ,Influence of the ...
Cached Biology News:Leader of Human Genome Project honored with the Inamori Ethics Prize 2New studies on the Mediterranean diet confirm its effectiveness for chronic disease prevention 2
... The Label IT siRNA Tracker Intracellular Localization ... directly label and deliver siRNA, of your ... for in vitro tracking experiments. Subcellular localization ... can be monitored following introduction of the ...
... The Label IT siRNA Tracker Intracellular ... provides a straight forward approach to ... your design, in an efficient yet ... experiments. Subcellular localization and functional inhibition ...
... and reproducible immunoprecipitation (IP) by using a 96 ... than regular IPs, which are problematic with regards ... the agarose bed. The binding of the antibody/antigen ... elution of the immune complex can occur with ...
... The Yeast Oligo Microarray Kit (V2), ... to simultaneously characterize expression of many ... gene activity during important biological processes. ... representing 6,256 known ORFs from the ...
Biology Products: